Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation

  title={Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation},
  author={Tomas Radivoyevitch and Rainer K. Sachs and Robert Peter Gale and Remco J. Molenaar and David J. Brenner and Brian T Hill and Matt E. Kalaycio and Hetty E. Carraway and Sudipto Mukherjee and Mikkael A. Sekeres and Jaroslaw P. Maciejewski},
Risks of acute myeloid leukemia (AML) and/or myelodysplastic syndromes (MDS) are known to increase after cancer treatments. Their rise-and-fall dynamics and their associations with radiation have, however, not been fully characterized. To improve risk definition we developed SEERaBomb R software for Surveillance, Epidemiology and End Results second cancer analyses. Resulting high-resolution relative risk (RR) time courses were compared, where possible, to results of A-bomb survivor analyses. We… 

Risk of subsequent myeloid neoplasms after radiotherapy treatment for a solid cancer among adults in the United States, 2000–2014

The findings support the importance of diagnostic precision in myeloid neoplasm classification since susceptibility following radiotherapy may vary by myelodysplasia-related changes, thereby informing risk/benefit discussions in first primary cancer treatment.

Sequential development of two separate therapy-related myeloid neoplasms following radiotherapy for prostate cancer

An extremely rare case with two separate t-MNs (therapy-related acute promyelocytic leukemia (t-APL) and t-MDS/AML) that sequentially developed following radiotherapy for prostate cancer that remained in complete remission for four years is reported.

Role of radiotherapy and chemotherapy in the risk of leukemia after childhood cancer: An international pooled analysis

A pooled analysis of all published studies with detailed treatment data, including estimated active bone marrow dose received during radiation therapy and doses of specific chemotherapeutic agents for childhood cancer diagnosed from 1930 through 2000, found topoisomerase II inhibitors were associated with increased SPL risk.

Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine

Data suggest that RAI treatment for WDTC is associated with increased risk of MDS with short latency and poor survival, and the increased risk was significantly associated with WDTC size ⩾2 cm or regional disease.

Risk of hematologic malignancies after breast ductal carcinoma in situ treatment with ionizing radiation

The data suggest that RT after breast conserving surgery for DCIS patients should be cautiously tailored, especially for low and intermediate-risk patients.

Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer.

RAI use in patients withWDTC should be limited to patients with high-risk disease features, and patients with WDTC treated with adjuvant RAI should be monitored for myeloid malignancies as part of cancer surveillance.

Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era

Large-scale, United States population-based data demonstrate excess tMDS/AML risks following chemotherapy for nearly all solid tumor types, consistent with expanded use of known leukemogenic agents in the 21st century.

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV

The increased SIR for NHL has to be considered and long-term follow-up of CML patients is warranted, as the rate of secondary malignancies may increase over time.

The risk of developing acute non-lymphocytic leukemia in women with breast cancer

Breast cancer survivors have a higher risk of developing subsequent ANLL compared to the general population and increased vigilance should be shown towards the potential development of ANLL due to older age, larger tumor size, chemotherapy, and radiation exposure in survivors.



Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990-2005

An elevated rate of MDS and AML was observed among breast cancer patients < 65, those treated with radiation and those treatedwith radiation and chemotherapy compared to available population incidence data.

Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation.

With relatively short follow-up, prostate cancer patients definitively treated with radiation did not appear to have a statistically increased risk of subsequent MDS, and rates were no higher than in population-based registries.

Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients.

Limiting exposure to alkylating agents and eliminating TBI from transplantation conditioning regimens may reduce the relative risk of tMDS/AML.

Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008.

Using long-term, population-based data, significant variation in tAML risk with time is observed, consistent with changing treatment practices and differential leukemogenicity of specific therapies.

Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis.

It is indicated that NHL patients experience a higher risk for SMNs than the general population and that various treatments have different impact on RR.

Sex differences in the incidence of chronic myeloid leukemia

It is suggested that sex differences in CML incidence more likely result from differences in risk than in latency, and comprehensive mathematical models of CML could lead to a better understanding of the role of HSCs in C ML and other preleukemias that can progress to acute leukemia.

The Incidence of Leukemia, Lymphoma and Multiple Myeloma among Atomic Bomb Survivors: 1950–2001

Analysis of radiation effects on leukemia, lymphoma and multiple myeloma incidence in the Life Span Study cohort of atomic bomb survivors updated 14 years since the last comprehensive report on these malignancies found that ERR models can often provide equivalent and sometimes more parsimonious descriptions of the excess risk than EAR models.

Reclassification of leukemia among A-bomb survivors in Nagasaki using French-American-British (FAB) classification for acute leukemia.

The present study suggests that the previously established leukemia types for about a quarter of the cases of acute leukemia and related disorders except CML should be changed.